XORTX Therapeutics Inc. (XRTX)
0.3791
+0.0341 (9.88%)
Inactive · Last trade price on Mar 27, 2026

XORTX Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.

Total Valuation

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Jan '22
34441226
Market Cap Growth
261.13%-4.38%-6.84%-63.14%-53.60%177.78%
Enterprise Value
232-1322
Last Close Price
0.380.561.132.317.2718.45

Price Ratios

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Jan '22
PB Ratio
1.231.881.230.951.701.94
P/TBV Ratio
1.352.061.300.981.751.97

Financial Efficiency

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Jan '22
Debt / Equity Ratio
0.020.020.010.000.01-
Net Debt / Equity Ratio
-0.40-0.40-0.73-0.74-1.48-1.13
Net Debt / EBITDA Ratio
0.330.330.940.711.126.48
Net Debt / FCF Ratio
0.300.300.660.521.263.10
Quick Ratio
1.581.583.294.256.9626.97
Current Ratio
2.112.113.534.937.2128.78
Return on Equity (ROE)
-98.00%-98.00%-83.06%-37.08%-76.43%-22.25%
Return on Assets (ROA)
-46.84%-46.84%-34.21%-34.72%-38.82%-15.04%
Return on Capital Employed (ROCE)
-121.80%-121.80%-78.40%-106.80%-85.10%-13.70%

Yields

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Jan '22
Earnings Yield
-103.59%-67.94%-81.03%-49.17%-64.82%-6.15%
FCF Yield
-107.98%-70.81%-89.96%-150.08%-68.74%-18.71%
Buyback Yield / Dilution
-64.48%-64.48%-45.25%-33.91%-35.25%-47.77%
SEC Filings: 10-K · 10-Q